Effectiveness and Safety of Oral Cordyceps sinensis on Stable COPD of GOLD Stages 2-3: Systematic Review and Meta-Analysis
Effectiveness and Safety of Oral Cordyceps sinensis on Stable COPD of GOLD Stages 2-3: Systematic Review and Meta-Analysis
复制标题
口服冬虫夏草对 GOLD 2-3 期稳定慢性阻塞性肺病的有效性和安全性：系统评价和荟萃分析
DOI：
10.1155/2019/4903671
复制
发表时间：
2019
影响因子：
--
通讯作者：
Xu Yinji
中科院分区：
文献类型：
--
作者：
Yu Xuhua;Mao Yuquan;Shergis Johannah Linda;Coyle Meaghan E;Wu Lei;Chen Yuanbin;Zhang Anthony Lin;Lin Lin;Xue Charlie Changli;Xu Yinji
冬虫夏草（Cordyceps sinensis，CS）是一种用于慢性阻塞性肺疾病全球倡议（GOLD）2 - 3期慢性阻塞性肺疾病（COPD）的补充药物。许多随机对照试验已经进行，以评估CS单独或与其他草药联合治疗稳定型COPD的效果。为了提供证据的综合，我们检索了2016年12月21日之前发表的关于CS的随机对照试验的9个主要电子数据库。15项干预性研究（包括1，238名受试者）符合纳入标准。Meta分析显示，CS制剂和CS配方均显示出在肺功能、运动耐力、生活质量和症状改善方面的潜在获益。未报告严重不良事件。因此，CS可能是GOLD 2 - 3期稳定型COPD患者的一种有希望的治疗方法。没有研究是安慰剂对照或高方法学质量的，这限制了结论。
Cordyceps sinensis(CS) is a complementary medicine used for Chronic Obstructive Pulmonary Disease (COPD) of Global Initiative for Chronic Obstructive Lung Disease (GOLD) stages 2‐3. Many randomized controlled trials have been conducted to evaluate the effect of CS alone or in combination with other herbs on stable COPD. To provide a synthesis of the evidence, we searched nine major electronic databases for randomized controlled trials on CS published before 21st December 2016. Fifteen interventional studies, including 1,238 participants, met the inclusion criteria. Meta‐analysis showed that both CS preparations and CS formulae showed the potential benefits in lung function, exercise endurance, life quality, and improvement of symptoms. No serious adverse events were reported. So CS may be a promising treatment for patients with stable COPD of GOLD stages 2‐3. No studies were placebo‐controlled or of high methodological quality, which limits the conclusions.